UCB SA (UNC0) Stock Price & Analysis
UNC0 Stock Chart & Stats
- Day’s Range
- EUR 139.00 - EUR 139.00
- 52-Week Range
- EUR 98.50 - EUR 142.00
- Previous Close
- EUR 134.00
- Volume
- 0
- Average Volume (3M)
- 28
- Market Cap
- EUR 53.46B
- Enterprise Value
- EUR 61.29B
- Total Cash (Recent Filing)
- EUR 796.67M
- Total Debt (Recent Filing)
- EUR 3.59B
- Price to Earnings (P/E)
- 24.4
- Beta
- 0.54
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 3.55
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.52%
Bulls Say, Bears Say
Bulls Say
Strong Growth And Guidance
UCB is delivering broad-based growth while also raising its outlook, indicating stronger commercial execution and operating leverage. If the upgraded trajectory persists, higher cash earnings should support continued investment in research, launches, and market expansion over the coming quarters.
BIMZELX Commercial Momentum
BIMZELX is becoming a major growth engine with rapid sales expansion, broad approvals, and adoption across multiple indications. Its scale and stated peak-sales potential can help offset older-product erosion and improve portfolio durability as UCB expands specialty-medicine leadership.
Improving Cash Generation
Stronger operating and free cash flow improves the quality of UCB's earnings and provides internally generated funding for R&D, commercialization, and selective business development. Better cash generation also strengthens resilience when product launches, reimbursement timing, or development spending fluctuate.
Bears Say
BRIVIACT Exclusivity Loss
The approaching loss of exclusivity creates a structural revenue headwind rather than a temporary market fluctuation. Generic erosion can remove a meaningful stream of established sales, requiring BIMZELX and other pipeline or growth products to replace lost contribution and protect portfolio earnings.
Pricing Pressure On BIMZELX
Broader access may support patient growth, but lower net pricing can reduce the economic value of each prescription and pressure margins during the transition. The business must therefore generate substantial incremental volume and maintain demand to ensure access expansion translates into durable revenue growth.
Acquisition-related Financial Burden
Higher debt and acquisition-related expenses can reduce financial flexibility and absorb part of the earnings benefit from strong product growth. Elevated interest and integration costs may constrain capital allocation until acquired assets contribute more fully and leverage is sustained at manageable levels.
UNC0 FAQ
What was UCB SA’s price range in the past 12 months?
What is UCB SA’s market cap?
When is UCB SA’s upcoming earnings report date?
How were UCB SA’s earnings last quarter?
Is UCB SA overvalued?
Does UCB SA pay dividends?
What is UCB SA’s EPS estimate?
How many shares outstanding does UCB SA have?
What happened to UCB SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of UCB SA?
What is the TipRanks Smart Score and how is it calculated?
UCB SA Stock Smart Score
Company Description
UCB SA
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jean-Christophe Tellier
- Employees
- 10,117
- Website
- www.ucb.com
- Address
- Allée de la Recherche, 60, Brussels, BU, 1070, BE
UCB SA (UNC0) Earnings & Revenues
UNC0 Company Deck
UNC0 Earnings Call
Earnings Call SentimentPositive
The call conveyed a strongly positive operational and financial performance in H1 2026: robust top-line growth, expanding margins and EBITDA, upgraded guidance, and clear commercial momentum for key growth drivers (notably BIMZELX) alongside meaningful pipeline and strategic acquisitions positioning the company for sustained longer-term growth. Notable risks include BRIVIACT loss of exclusivity with large expected sales declines, anticipated net price pressure from recent access wins (near-term H2 price erosion before volume benefits), increased G&A and integration costs from acquisitions, and competition/heterogeneity risks in HS. On balance, the positive execution, upgraded guidance and attractive pipeline developments outweigh the near-term headwinds.
View all DE:UNC0 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
